Last C$0.09 CAD
Change Today 0.00 / 0.00%
Volume 122.8K
As of 3:08 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

verisante technology inc (VRS) Snapshot

Open
C$0.08
Previous Close
C$0.09
Day High
C$0.09
Day Low
C$0.08
52 Week High
01/8/14 - C$0.28
52 Week Low
12/17/14 - C$0.08
Market Cap
7.3M
Average Volume 10 Days
90.1K
EPS TTM
C$-0.05
Shares Outstanding
86.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERISANTE TECHNOLOGY INC (VRS)

Related News

No related news articles were found.

verisante technology inc (VRS) Related Businessweek News

No Related Businessweek News Found

verisante technology inc (VRS) Details

Verisante Technology, Inc., a medical device company, develops and commercializes skin cancer detection systems. The company’s products include Verisante Aura, a spectroscopy system to aid in the detection of various skin cancers, including basal cell carcinoma, squamous cell carcinoma, melanoma, pre-cancerous lesions, and actinic keratosis; and Verisante Core for the detection of other types of cancer, including lung, gastro-intestinal, colorectal, and cervical cancers. It has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology, Inc. in January 2011. Verisante Technology, Inc. was founded in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

verisante technology inc (VRS) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: C$312.5K
Chief Financial Officer, Corporate Counsel an...
Total Annual Compensation: C$165.3K
Compensation as of Fiscal Year 2012.

verisante technology inc (VRS) Key Developments

Verisante Technology, Inc. Presents at Emerging Medical Technologies Summit, Nov-11-2014 02:40 PM

Verisante Technology, Inc. Presents at Emerging Medical Technologies Summit, Nov-11-2014 02:40 PM. Venue: Sofitel Hotel San Francisco, 223 Twin Dolphin Dr., Redwood City, CA 94065, United States. Speakers: Thomas A. Braun, Chief Executive Officer, President, Director, Member of Compensation Committee and Member of Audit Committee.

Verisante Technology, Inc. Initiates Communications with FDA in the United States for the Approval of Aura

Verisante Technology, Inc. announced it has initiated communications with the Food and Drug Administration (FDA) in the United States for the approval of Aura, a device for the detection of skin cancer. Verisante has now submitted documents to the FDA as it begins the formal application process for approval to market and sell Aura in the United States.

Verisante Technology Forms Joint Venture with Undisclosed Chinese Partner

Verisante Technology announced that it has re-negotiated the terms of a letter of intent with an undisclosed Chinese company. Under the new terms, the company will sublicense worldwide rights to develop and commercialize the Core Raman technology with the ClearVu endoscopic camera system for the detection of lung cancer, along with China marketing rights for other Core series products into a jointly owned company. Verisante will have a 30% interest in the joint venture, which will be an LLC listed in the Chinese OTC market. Other terms include a $2.15 million equity investment in Verisante by the Chinese partner, the LLC funding the development and commercialization of the Core device, and the LLC paying Verisante a $1 million development fee upon regulatory approval and sale of the LLC's first Core product.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRS:CN C$0.09 CAD 0.00

VRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.45 USD 0.00
Cascade Technologies Corp $0.0049 USD +0.0004
Mauna Kea Technologies €5.61 EUR +0.05
Medx Health Corp C$0.08 CAD 0.00
Optiscan Imaging Ltd A$0.04 AUD +0.002
View Industry Companies
 

Industry Analysis

VRS

Industry Average

Valuation VRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 99.6x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 104.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERISANTE TECHNOLOGY INC, please visit www.verisante.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.